Pharma - Industry – Focus

 

Custom Search

Technology Trends

Advinus Therapeutics plans expansion of drug discovery programme

Advinus Therapeutics is planning an expansion programme with an investment of Rs. 3000 million. The company promoted with funding from Tata Group to the tune of Rs.2000 million in 2005 had recently discovered a new drug moleculed "GKM-001" for type II diabetics. It is expanding its human resources and plans to double its development programmes from current 6-7 to 13-14 programmes. It will also look at drugs for aged like Parkinson's, Alzheimer's, frailty, arthritis and brittle bones. Advinus would double the Pune team to 500 and add 50 more to the Bangalore team of 350, taking the total to 900. The company, which runs on the model of contract research for global partners at Bangalore and drug discovery done at Pune, expects to touch a turnover of Rs 100 crore this fiscal

India Glycols to expand Super Critical Fluid Extraction (SCFE) Unit at Selaqui


India Glycols to expand Super Critical Fluid Extraction (SCFE) Unit  at Selaqui in Dehradun in Uttaranchal. The project involves expanding natural health production unit from 150 to 1050 kg/day with an investment of Rs. 40 million. Herbal raw materials like Ginger, Turmeric, Chilly, Stevia, Rosemary, Pyrethrum and Chemomomile etc. will be used to manufacture natural products.  More than 50 products will be manufactured.  Super Critical Fluid (i.e. CO2) Extraction Technology; Aqueous and Aqueous Alcoholic Recycling Batch Extraction Process; Aqueous Open Vessels Live Steam Heated Extraction Process and Semi-Mechanized Steam Distillation Process will be used for the production of natural health products.

Novavax and Cadilla forms joint-venture to conduct research on VLP vaccines

Cadilla Pharmaceuticals and US based biotech firm Novavax has formed a 80:20 joint-venture to conduct research and commercializing virus-like-particle (VLP) based vaccines. It seems, Cadilla will invest USD 8 million and Novavax will bring the technology. The deal will also help to commercialize Cadilla’s therapeutic vaccine candidates against cancer as well adjutants, bio generic products in India.

It has formed CPL Biologicals Private Limited, a new joint venture company and plans to set up a  new ‘Virus Like Particles’ (VLP) plant by 2011. Currently, it operates from CPL existing unit and it may have its own unit by two years time. VLP technology will help to reduce vaccine making time by 50% and the new plant may entail investment of Rs.1000 million. It will focus to produce H1N1 influenza vaccine (also called swine flu vaccine).

Bharat Biotech launches new COMVAC5, a single shot pentavalent vaccine

 Bharat Biotech International Ltd, a Hyderabad based company that manufactures vaccines launched COMVAC5, a single shot vaccine which offers protection against haemophilus influenza, meningitis etc and contains tetanus, Hepatitis B, Hib, Pertusis, Diptheria. It is the first of kind of Hib vaccine manufactured indigenously without using cesium chloride.

 

 

Custom Search

Copyright © 2013 Ibis Research Information Services Pvt Ltd. All Rights Reserved.
Contact : Ibis Research Information Services Pvt Ltd., 28, Rajaji Street, NGO Colony
Guduvancherry, Chennai -603 202   Mobile : 0-97898-37940 email : ibischennai@gmail.com Privacy Policy